Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

OpEd: To save patients, protect biotech

4/17/2015

0 Comments

 
Trenton, NJ - Debbie Hart, president and CEO of BioNJ, and Dean Paranicas, president and CEO of the HealthCare Institute of New Jersey, write a great opinion article in the Courier Post, discussing the success of the New Jersey biopharma industry.
Here is what they wrote:

New Jersey is an AIDS “hotspot,” according to CBS News. The statistics show why. In 2012, nearly 2,000 state residents were diagnosed with HIV/AIDS. Roughly 400 people died from the disease.

Thanks to advances in treatment, however, this disease is no longer a death sentence. Fatality rates from AIDS have dropped nearly 85 percent over the last two decades, and are still declining.

But the future of medical progress is far from certain. In fact, some politicians in Washington are advocating for new measures that could impede life sciences innovation for years to come. Their proposals would jeopardize patient health and put a vital segment of New Jersey’s economy at risk.

The fight against AIDS is a clear example of how biopharmaceutical research saves lives. However, AIDS isn’t the only biopharma success story. Patients with conditions from diabetes to cancer enjoy longer, healthier lives thanks to recent advances in biopharmaceutical treatment.

Despite these life-saving advancements, we continue to face formidable medical challenges. That is why teams of scientists at biopharmaceutical and biotechnology companies here in New Jersey and across the nation work daily to research and discover the next generation of medical innovations that will alleviate other life-threatening diseases.

Last year, the U.S. Food and Drug Administration approved 41 new medications — the highest number since 1996. These included new Hepatitis C treatments that boast cure rates of over 90 percent as well as the first immunotherapies for cancer.

More good news: If research and development spending is any indication, more cures are on the way. Biopharmaceutical companies, which have long been an invaluable part of the New Jersey economy, are investing heavily in R&D. Nationwide, the industry spent over $51 billion creating new treatments, cures and diagnostic tools in 2012.

That spending contributes greatly to the Garden State’s economy. New Jersey’s life sciences industry contributed $30.1 billion to the state’s economy in 2013. What’s more, biopharmaceutical innovation creates jobs. Local life sciences firms directly employ over 66,000 people. The industry indirectly support another 146,000 workers.

In addition, in 2013, New Jersey biopharmaceutical companies had more than 9,300 vendor relationships throughout the state. They purchased nearly $6.4 billion in goods and services from these local businesses.

In short, biopharma and biotech firms are an integral part of the state’s economy. But now, short-sighted legislation could stifle this economic progress.

One such threat is patent litigation legislation, which is currently being considered by Congress. While certain advocates tout the proposal as a way to cut down on unfounded patent lawsuits, in reality, as presented, the law would make protecting intellectual property a costly, time-consuming process.

Given that patents play an essential role in the life sciences industry, the proposed reform poses a direct threat to the future of medical innovation. If life sciences firms are unable to protect their inventions from theft in a court of law, they will have little incentive to risk their huge investments in new research.

Another major threat from Washington faced by New Jersey’s biopharmaceutical and biotechnology companies relates to the president’s budget, which proposes drastic changes to Medicare Part D, the prescription drug benefit for the nation’s seniors.

If passed, price controls on certain drugs, in effect, would be imposed, requiring drug makers to sell medicines to the government at costs far below the investment in R&D necessary to discover new medical treatments and cures.

The impact would be harsh and far-reaching. The lost revenue for life sciences companies would mean a diversion of funds from R&D of new medicines, fewer jobs in New Jersey, and, most importantly, fewer treatments for devastating illnesses.

Researching and taking a new medicine to the global marketplace is complex, high-risk, time-consuming and extremely costly. Today, it often takes longer than a decade and costs about $2.6 billion to research and develop a new drug and bring it to market. Consequently, if biopharmaceutical and biotechnology firms scale back on drug development, we will see fewer new cures — and a slowdown in job creation and economic growth.

New Jersey’s representatives in Washington have long recognized the importance of fostering and protecting the innovation environment that is critical to finding the next generation of treatments and cures.

We urge our policymakers to continue protecting patients and New Jersey’s economy by rejecting ill-conceived and anti-innovation proposals that could detrimentally impact our state’s economic well-being, and, more importantly, patients’ well-being here at home and around the globe.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
222 West State Street
Suite 302
Trenton, NJ 08608
732-729-9619